Cargando…
Combined application of rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease
Atherosclerosis arising from the pro-inflammatory conditions associated with chronic kidney disease (CKD) increases major cardiovascular morbidity and mortality. Rapamycin (RAPA) is known to inhibit atherosclerosis under CKD and non-CKD conditions, but it can cause dyslipidemia; thus, the co-applica...
Autores principales: | Song, Eun Ju, Ahn, Sanghyun, Min, Seung-Kee, Ha, Jongwon, Oh, Goo Taeg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016660/ https://www.ncbi.nlm.nih.gov/pubmed/33050984 http://dx.doi.org/10.5483/BMBRep.2021.54.3.136 |
Ejemplares similares
-
Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1(+/−) Mice
por: Shen, Ming Hong, et al.
Publicado: (2017) -
Association of high intra-patient variability in tacrolimus exposure with calcineurin inhibitor nephrotoxicity in kidney transplantation
por: Kim, Hyokee, et al.
Publicado: (2023) -
Klotho as a potential predictor of deceased donor kidney transplantation outcomes
por: Kim, Suh Min, et al.
Publicado: (2020) -
The appearance of C1q deposition in transplanted kidney allografts and its clinical and histopathologic features
por: Jo, Eun-Ah, et al.
Publicado: (2022) -
Atorvastatin upregulates apolipoprotein M expression via attenuating LXRα expression in hyperlipidemic apoE-deficient mice
por: Liu, Jian, et al.
Publicado: (2018)